Arcus Biosciences
RCUS
193 hedge funds and large institutions have $791M invested in Arcus Biosciences in 2024 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 62 increasing their positions, 63 reducing their positions, and 21 closing their positions.
105% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 21
55% more call options, than puts
Call options by funds: $3.58M | Put options by funds: $2.31M
12% more funds holding
Funds holding: 172 → 193 (+21)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 63
1.07% less ownership
Funds ownership: 58.16% → 57.1% (-1.1%)
21% less capital invested
Capital invested by funds: $997M → $791M (-$207M)
Top Buyers
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$22M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.52M |
| 3 |
Goldman Sachs
New York
|
+$6.24M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.41M |
| 5 |
TI
Trexquant Investment
Stamford,
Connecticut
|
+$3.46M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$29.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.66M |
| 3 |
Morgan Stanley
New York
|
-$6.92M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$4.54M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$4.53M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
201
American International Group
New York
| – | -$548K | -29,014 | Closed |
|
|
NYLIM
202
New York Life Investment Management
New York
| – | -$404K | -21,416 | Closed |
|
|
MAM
203
Martingale Asset Management
Boston,
Massachusetts
| – | -$374K | -19,825 | Closed |
|
204
Walleye Capital
New York
| – | -$334K | -17,691 | Closed |
|
|
EFM
205
E Fund Management
Guangzhou,
China
| – | -$303K | -16,052 | Closed |
|
206
ProShare Advisors
Bethesda,
Maryland
| – | -$205K | -10,846 | Closed |
|
|
HT
207
Headlands Technologies
Chicago,
Illinois
| – | -$59.3K | -3,139 | Closed |
|
|
MLICM
208
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$54.2K | -2,870 | Closed |
|
|
QL
209
Quarry LP
New York
| – | -$51.9K | -2,750 | Closed |
|
210
KBC Group
Brussels,
Belgium
| – | -$37K | -1,952 | Closed |
|
|
S
211
SignatureFD
Atlanta,
Georgia
| – | -$1.26K | -67 | Closed |
|
|
RAM
212
Riggs Asset Management
Dallas,
Pennsylvania
| – | -$359 | -19 | Closed |
|
|
AWM
213
Avior Wealth Management
Omaha,
Nebraska
| – | -$188 | -10 | Closed |
|
|
C
214
Covestor
London,
United Kingdom
| – | +$48 | +3 | +75% |
|
RCUS Hedge Fund Activity: Q2 2024 in Review
193 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2024, worth a combined $791M — down 21% from $997M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new RCUS positions and 21 closed out — a net gain of 22 holders — while 62 added to existing stakes and 63 trimmed.
The largest buyer was Woodline Partners, adding an estimated $22M. The largest seller was State Street, cutting an estimated $29.9M.
- 193 institutional investors held Arcus Biosciences (RCUS) as of Q2 2024, up from 172 in Q1 2024.
- Funds reported $791M of Arcus Biosciences stock for Q2 2024, down 21% quarter-over-quarter.
- 43 funds opened new Arcus Biosciences positions in Q2 2024 and 21 closed out, a net change of +22 holders.
- The largest Arcus Biosciences buyer in Q2 2024 was Woodline Partners, an estimated $22M added.
- The largest Arcus Biosciences seller in Q2 2024 was State Street, an estimated $29.9M sold.
Based on aggregated 13F filings for Q2 2024.